New England Journal of Medicine
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
New England Journal of Medicine
Jul 15, 2024, 08:52 |
Blog
Raffaele Colombo: Tisotumab vedotin as 2nd or 3rd line therapy for recurrent cervical cancer
Raffaele Colombo shared a post on X about recent paper by Ignace Vergote et al.…
Jul 1, 2024, 15:01 |
Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 26, 2024, 12:05 |
Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 24, 2024, 15:19 |
Insight
Vivek Subbiah: Precision therapy with ALK inhibitor in ALCL
Vivek Subbiah shared on X: . "Precision therapy with anaplastic lymphoma…
Jun 23, 2024, 14:07 |
Blog
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
Mark Roschewski, Senior Clinician in the Lymphoid Malignancies Branch at the National Cancer Institute, shared a…
Jun 20, 2024, 07:48 |
Blog
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Vivek Subbiah shared a post on X: "Risk of Second Tumors and T-Cell Lymphoma after CAR…
Jun 8, 2024, 02:16 |
Blog
Toni Choueiri: NICHE-2 by Myriam Chalabi published in NEJM
Toni Choueiri shared a post on X: , "NICHE-2 published…
May 13, 2024, 08:08 |
Blog
Monica Bertagnolli: Fascinating research I recently read about CAR-T therapy
Monica Bertagnolli shared a post on LinkedIn: ''Fascinating research I recently read about in the New…
May 1, 2024, 17:02 |
Opinion
Uri Ilan: This isn't the first time we've seen AI in the exam room
Uri Ilan, Researcher PhD Student, Coordinator of the International Leukemia/Lymphoma Target Board, shared a post…
May 1, 2024, 10:59 |
Blog
Michael Kupferman: Madappa Kundranda sat down with Arizona PBS Horizon to discuss a potential new way to screen for colorectal cancer
Michael Kupferman, Senior Vice President at Banner Health, shared a post on LinkedIn: "Banner MD…
Apr 28, 2024, 14:27 |
Blog
Michael D. : Meet the Master-Hands of Medicine
Michael D., Support Analyst at Sarah Cannon Research Institute, shared a post by Vivek Subbiah…
Apr 25, 2024, 20:18 |
Positive
Vivek Subbiah: HUGE MILESTONE in all of medicine and a huge win for patients and families with sickle cell disease and β-Thalassemia
Quoting Vivek Subbiah's post on X/Twitter: "Hot off the press! HUGE MILESTONE in all of…
Apr 9, 2024, 09:03 |
Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Apr 8, 2024, 14:54 |
Insight
Piotr Wysocki: New data solidify the idea of omitting axillary dissection in breast cancer patients with clinically N0 disease and macrometastases in 1-2 sentinel LN
Piotr Wysocki, Head of the Clinical Oncology Department at Jagiellonian University Hospital, shared on LinkedIn:…
Apr 7, 2024, 03:41 |
Insight
Sarah Sammons: How do we tailor adjuvant therapy without axillary dissection?
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, recently shared a post by Massimo…
Apr 5, 2024, 18:16 |
Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Feb 21, 2024, 18:18 |
Insight
Vivek Subbiah: As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products
Vivek Subbiah shared on LinkedIn: "Perspective article on 'Secondary Cancers after Chimeric Antigen Receptor T-Cell…
Feb 5, 2024, 11:19 |
Insight
Vivek Subbiah: When the New England Journal of Medicine publishes a Phase 1 study in any field, you know it's a game-changer
Vivek Subbiah shared on LinkedIn: ''When the New England Journal of Medicine publishes a Phase 1…
Jan 5, 2024, 15:00 |
Blog
An important step in improving the diagnostic challenges in AVP-D - Histiocytosis Association
Histiocytosis Association recently posted on LinkedIn: "We recently learned of a new article on copeptin-based…
Nov 1, 2023, 18:31 |
Drugs
David Sebag-Montefiore: We strongly caution against the use of FOLFOX alone applied to the whole PROSPECT trial population
David Sebag-Montefiore shared on LinkedIn: "Delighted to see our letter published in the New England Journal…
Sep 3, 2023, 17:26 |
Opinion
Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.
Paz Polak, VP of Computational Biology, C2i Genomics, recently posted on LinkedIn: "In a correspondence…
All:
21
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube